BOLT
Bolt Biotherapeutics
NASDAQ: BOLT · HEALTHCARE · BIOTECHNOLOGY
$4.87
+2.21% today
Updated 2026-04-30
Market cap
$9.28M
P/E ratio
—
P/S ratio
1.21x
EPS (TTM)
$-17.85
Dividend yield
—
52W range
$4 – $9
Volume
0.0M
Bolt Biotherapeutics (BOLT) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-83.7%
Last 4 quarters
Revenue YoY growth
-89.6%
Most recent quarter
EPS YoY growth
-610.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+4.9%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+12.1%
2026-03-13
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-13 | $-2.98 | +46.0% | $4.05 | $4.54 | +12.1% |
| 2025-11-12 | $-3.72 | -1140.0% | $4.81 | $4.70 | -2.3% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-5.52 | $-2.98 | +46.0% | $2.50M | -89.6% |
| 2025-09-30 | $-0.30 | $-3.72 | -1140.0% | $2.17M | +90.1% |
| 2025-06-30 | $-0.31 | $-4.46 | -1338.7% | $1.80M | +41.5% |
| 2025-03-31 | $-0.36 | $-0.29 | +19.4% | $1.22M | -76.8% |
| 2024-12-31 | $-0.35 | $-0.42 | -20.0% | $24.09M | +1053.3% |
| 2024-09-30 | $-0.40 | $-0.40 | -1.3% | $1.14M | -54.9% |
| 2024-06-30 | $-0.48 | $-0.46 | +4.2% | $1.27M | -11.0% |
| 2024-03-31 | $-0.51 | $-0.28 | +45.1% | $5.27M | +188.8% |
| 2023-12-31 | $-0.48 | $-0.47 | +2.1% | $2.09M | — |
| 2023-09-30 | $-0.50 | $-0.43 | +14.0% | $2.53M | — |
| 2023-06-30 | $-0.49 | $-0.48 | +2.0% | $1.43M | — |
| 2023-03-31 | $-0.51 | $-0.45 | +11.8% | $1.83M | — |
Frequently asked questions
Has Bolt Biotherapeutics beaten earnings estimates?
Bolt Biotherapeutics has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -83.7% over the last 4 quarters.
How does BOLT stock react to earnings?
BOLT stock has moved an average of +4.9% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Bolt Biotherapeutics's revenue growth rate?
Bolt Biotherapeutics reported year-over-year revenue growth of -89.6% in its most recent quarter, with EPS growing -610.0% year-over-year.